SCHEMBL23022201

SCHEMBL23022201

CCOC(=O)c1cnn(-c2nc(Br)cnc2N)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.46
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 2/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
LMNA P02545 2/20 0.38
HSD17B10 Q99714 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAOA P21397 1/20 0.38
KDM4E B2RXH2 2/20 0.38
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
CSNK1D P48730 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
PIK3CD O00329 1/20 0.37
PIK3R1 P27986 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31448269 1.00 ADORA2A (0.46) ADORA2ANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL29507151 0.80 ALKBH2 (0.46) PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG
SCHEMBL31448239 0.80 PIK3CD (0.47) ADORA2ASMN1; SMN2PIK3CDPIK3R1PIK3CA
SCHEMBL23012663 0.80 ALKBH2 (0.46) PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG
SCHEMBL23022181 0.79 ADORA2A (0.43) ADORA2AKMT2APIK3CDPIK3R1PIK3CA
SCHEMBL23012515 0.77 DHFR (0.33) SMN1; SMN2TSHRMAPTLMNAKMT2A
SCHEMBL15904017 0.76 ADORA2A (0.49) ADORA2AALDH1A1SMN1; SMN2TSHRLMNA
SCHEMBL31448242 0.76 CHEK1 (0.54) MAPTLMNAPIK3CDPIK3R1PIK3CA
SCHEMBL25431180 0.76 MAOB (0.45) ADORA2ANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL30535573 0.76 MAOB (0.45) ADORA2ANPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114341127-B Aminopyrazine compounds as HPK1 inhibitors and uses thereof 百济神州有限公司 2024-12-17 CN disclosed
US-20220289712-A1 AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2022-09-15 US disclosed
CN-114341127-A Aminopyrazine compounds as HPK1 inhibitors and uses thereof 百济神州有限公司 2022-04-12 CN disclosed
WO-2021032148-A1 AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF BEIGENE, LTD. (KY) 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289712-A1 AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF MAPKAPK5, STK25, STK35 ADORA2A 3042/4885NPC1 1003/4885RAB9A 2731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.